Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2006 | Guidelines

EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues

Authors: T. Vander Borght, S. Asenbaum, P. Bartenstein, C. Halldin, Ö. Kapucu, K. Van Laere, A. Varrone, K. Tatsch

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2006

Excerpt

These guidelines summarise the views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of PET or SPECT imaging of brain tumours using radiolabelled amino acid analogues. The aim is to help in achieving a high quality of tumour imaging using radiolabelled amino acids, which will allow the diagnostic impact of this technique in neuro-oncological practice to be increased. …

Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45PubMed

Langen KJ, Pauleit D, Coenen HH. 3-[¹²³I]Iodo-α-methyl-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2002;29:631

Laverman P, Boerman OC, Corstens FH, Oyen WJ. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med Mol Imaging 2002;29:681–690PubMedCrossRef

Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [¹¹C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163–7170PubMedCrossRef

Pauleit D, Floeth F, Herzog H, Hamacher K, Tellmann L, Müller HW, et al. Whole-body distribution and dosimetry of O-(2-[¹⁸F]fluoroethy)-L-tyrosine. Eur J Nucl Med Mol Imaging 2003;30:519–524PubMedCrossRef

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of¹⁸F-FDG and¹¹C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004;45:1293–1298PubMed

Riemann B, Papke K, Hoess N, Kuwert T, Weckesser M, Matheja P, et al. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. Radiology 2002;225:567–574PubMed

Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, et al. Methyl-[¹¹C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868–873PubMedCrossRef

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–750PubMedCrossRef

10.

Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146–1154PubMed

11.

Lahoutte T, Caveliers V, Franken PR, Bossuyt A, Mertens J, Everaert H. Increased tumor uptake of 3-¹²³I-iodo-L-alpha-methyltyrosine after preloading with amino acids: an in vivo animal imaging study. J Nucl Med 2002;43:1201–1206PubMed

12.

Deloar HM, Fujiwara T, Nakamura T, Itoh M, Imai D, Miyake M, et al. Estimation of internal absorbed dose of L-[methyl-¹¹C]methionine using whole-body positron emission tomography. Eur J Nucl Med 1998;25:629–633PubMedCrossRef

13.

Schmidt D, Langen KJ, Herzog H, Wirths J, Holschbach M, Kiwit JC, et al. Whole-body kinetics and dosimetry of L-3-¹²³I-iodo-alpha-methyltyrosine. Eur J Nucl Med 1997;24:1162–1166PubMed

14.

Kuwert T, Morgenroth C, Woesler B, Matheja P, Palkovic S, Vollet B, et al. Uptake of iodine-123-alpha-methyl tyrosine by gliomas and non-neoplastic brain lesions. Eur J Nucl Med 1996;23:1345–1353PubMedCrossRef

15.

Kuwert T, Woesler B, Morgenroth C, Lerch H, Schafers M, Palkovic S, et al. Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 1998;39:23–27PubMed

16.

Weber WA, Dick S, Reidl G, Dzewas B, Busch R, Feldmann HJ, et al. Correlation between postoperative 3-[¹²³I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144–1150PubMed

17.

Van Laere K, Ceyssens S, Van Calenbergh F, de Groot T, Menten J, Flamen P, et al. Direct comparison of¹⁸F-FDG and ¹¹C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39–51PubMedCrossRef

18.

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Muller HW, et al. O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678–687PubMedCrossRef

19.

Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363–1378PubMedCrossRef

Title: EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues
Authors: T. Vander Borght
S. Asenbaum
P. Bartenstein
C. Halldin
Ö. Kapucu
K. Van Laere
A. Varrone
K. Tatsch
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-006-0206-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2006

Risk assessment in liposarcoma patients based on FDG PET imaging

PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT

[111In]DOTATOC as a dosimetric substitute for kidney dosimetry during [90Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach

99mTc-NC100668, a new tracer for imaging venous thromboemboli: pre-clinical biodistribution and incorporation into plasma clots in vivo and in vitro

FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy

124I in PET imaging: impact on quantification, radiopharmaceutical development and distribution